• 2mg modified-release tablets (prescribe generically)
• 1mg, 2mg, 3mg, 4mg, 5mg tablets (Adaflex^®, crushed if necessary)
•  restricted use: 1mg/ml oral solution (Consilient brand). Restricted to people not able to swallow tablets and not able to have Adaflex^®

NB: Slenyto is no longer approved. Established patients can continue to be prescribed Slenyto in primary care. Patients established on Slenyto should be reviewed at their next routine follow-up with their specialist, with a view to discontinuing or switching to a formulary product where clinically appropriate. See separate formulary entry for Slenyto. 

Approved Indications

• Insomnia (short term use – Max 13 weeks) adults 55 years and over

• Delayed sleep phase syndrome and other circadian rhythm disorders (including visually impaired/blind people with disturbed sleep wake cycles)
• Patients with injurious parasomnia including REM sleep behaviour disorder (RBD) [e.g with degenerative conditions such as Parkinsonian disease or dementia]
• Sleep conditions in patients with learning disabilities and behaviour that challenges (where sleep hygiene measures have been insufficient)
• Neurological or behavioural disorders including:
  • Attention deficit hyperactivity disorder (ADHD)
  • Autism Spectrum Disorder (ASD)
  • Neurodevelopmental disabilities  
• Cluster headache 
• Prior to examinations as directed by paediatric specialists (such as a sleep encephalogram (EEG) & sedation prior to scans)

• Critical care short term sleep disturbance [Hospital use only]

Indications not listed on the formulary are not routinely supported for prescribing e.g. sleep disturbances related to shift work, Alzheimer's disease, chronic fatigue syndrome / myalgic encephalomyelitis / encephalopathy, sleep apnoea, as an adjunct to hypnotic withdrawal and jet lag (unless an approved indication co-exists)

Not considered a cost-effective formulation. 

Established patients can continue to be prescribed Slenyto in primary care. Patients established on Slenyto should be reviewed at their next routine follow-up with their specialist, with a view to discontinuing or switching to a formulary product where clinically appropriate.

See separate formulary entry for approved melatonin formulations.